Mantle Cell Lymphoma, An Issue of Hematology/Oncology Clinics of North America

1st Edition, Volume 34-5 - September 2, 2020
Editor: John P. Leonard
Language: English
Hardback ISBN:
9 7 8 - 0 - 3 2 3 - 7 6 3 1 2 - 7
eBook ISBN:
9 7 8 - 0 - 3 2 3 - 7 6 3 1 3 - 4

This issue of Hematology/Oncology Clinics, Guest Edited by Dr. John P. Leonard, is devoted to Mantle Cell Lymphoma. This issue is one of six selected each year by our series… Read more

Mantle Cell Lymphoma, An Issue of Hematology/Oncology Clinics of North America

Purchase options

Info / Buy

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code is needed.

Institutional subscription on ScienceDirect

Request a sales quote

This issue of Hematology/Oncology Clinics, Guest Edited by Dr. John P. Leonard, is devoted to Mantle Cell Lymphoma. This issue is one of six selected each year by our series Consulting Editors, George P. Canellos and Edward J. Benz. Topics discussed in this important issue include: Molecular pathogenesis of Mantle Cell Lymphoma; MCL and cell cycle dysregulation; Heterogeneity in MCL biology and outcomes; Watch and wait in mantle cell lymphoma; Limited stage mantle cell lymphoma; Initial and consolidation therapy for younger patients with MCL; Approach to the initial treatment of older patients with MCL; Current and future approaches to the use of minimal residual disease monitoring in the treatment of patients with MCL; Bruton’s Tyrosine Kinase inhibitors for treatment of Mantle Cell Lymphoma; BTKi resistance in MCL; Blastoid MCL; Allogeneic transplant and CAR-T cell therapy in MCL; Quality of life considerations and chronic therapy in management of patients with MCL; and Key clinical and translational research questions.

Cover image
Title page
Table of Contents
Copyright
Contributors
Forthcoming Issues
Preface
Molecular Pathogenesis of Mantle Cell Lymphoma
Key points
Introduction
Translocation t(11;14) and overexpression of cyclin D1
Variant CCND1 translocations and expression in mantle cell lymphoma
Cyclin D1–negative mantle cell lymphoma
SOX11: a key oncogenic factor
Mantle cell lymphoma molecular subtypes: distinct pathogenic pathways
From early lesions to an overt lymphoma
The hallmarks of cancer in mantle cell lymphoma
Summary
Cell Cycle Dysregulation in Mantle Cell Lymphoma: Genomics and Therapy
Key points
Introduction
Genomic aberrations in key cell cycle genes in mantle cell lymphoma cells
Genomic aberrations in ATM, TP53, MYC, and BTK in mantle cell lymphoma
Targeting CDK4/6 in mantle cell lymphoma
Palbociclib
Palbociclib in sequential combination with bortezomib
Palbociclib in combination with ibrutinib
Other CDK4/6 inhibitors
Discussion
Contributions
What Is Responsible for Heterogeneity in Mantle Cell Lymphoma Biology and Outcomes?
Key points
Introduction
Differences in clinical presentation
Heterogeneity in laboratory features
Differences in tumor imaging
Summary
Watch and Wait in Mantle Cell Lymphoma
Key points
Introduction
Predictors and outcomes of deferred therapy in mantle cell lymphoma
Advantages and disadvantages of watch and wait
Future directions
Summary
Is Limited-Stage Mantle Cell Lymphoma Curable and How Is It Best Managed?
Key points
Introduction
Epidemiology of limited-stage mantle cell lymphoma
In situ mantle cell neoplasia
Rationale for radiation therapy in the treatment of limited-stage mantle cell lymphoma
Deferred therapy for limited-stage mantle cell lymphoma
Summary of retrospective studies for the treatment of limited-stage mantle cell lymphoma
Is limited-stage mantle cell lymphoma curable?
Recommended approach to limited-stage mantle cell lymphoma
Initial and Consolidation Therapy for Younger Patients with Mantle Cell Lymphoma
Key points
Consolidation with autologous stem cell transplantation
Future directions
Summary
Approach to the Initial Treatment of Older Patients with Mantle Cell Lymphoma
Key points
Introduction
Initial treatment with chemoimmunotherapy
The potential of chemotherapy-free initial therapy
Minimal residual disease and response-adapted strategies
Summary
Minimal Residual Disease in Mantle Cell Lymphoma: Methods and Clinical Significance
Key points
Introduction
Techniques for minimal residual disease analysis
How minimal residual disease data have affected therapeutic paradigms in mantle cell lymphoma
Summary
Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma
Key points
Introduction
Currently approved agents and indications
Ibrutinib
Acalabrutinib
Zanubrutinib
Alternative Bruton tyrosine kinase inhibitors
Options for progression after Bruton tyrosine kinase inhibitors
Combination therapy relapsed and refractory
Summary
What Causes Bruton Tyrosine Kinase Inhibitor Resistance in Mantle Cell Lymphoma and How Should We Treat Such Patients?
Key points
Introduction
Bruton tyrosine kinase inhibitor outcomes in mantle cell lymphoma
Outcomes in patients with Bruton tyrosine kinase inhibitor resistance
Mechanisms of Bruton tyrosine kinase inhibitor resistance
Therapeutic approaches to combat Bruton tyrosine kinase inhibitor resistance
Summary
Blastoid Mantle Cell Lymphoma
Key points
Introduction
Summary and future directions
Allogeneic Transplantation and Chimeric Antigen Receptor-Engineered T-Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma
Key points
Introduction
Allogeneic hematopoietic stem cell transplantation for relapsed and refractory mantel cell lymphoma
Chimeric antigen receptor-engineered T-cell therapy for relapsed and refractory mantel cell lymphoma
Summary
Understanding Health-Related Quality of Life in Patients with Mantle Cell Lymphoma
Key points
Introduction
Why is understanding health-related quality of life particularly relevant in patients with mantle cell lymphoma?
Health-related quality of life in patients with newly diagnosed mantle cell lymphoma
Health-related quality of life in patients with relapsed/refractory Mantle cell lymphoma
Challenges in the evaluation of health-related quality of life in Mantle cell lymphoma
Future directions and summary
Key Clinical and Translational Research Questions to Address Unmet Needs in Mantle Cell Lymphoma
Key points
Introduction
Question 1: for young fit patients, can we replace intensive induction regimens with alternatives incorporating less toxic, more effective novel agents?
Question 2: can we use minimal residual disease status as response-adapted therapy for mantle cell lymphoma?
Question 3: will chimeric antigen receptor T-cell therapy represent a cure for mantle cell lymphoma?
Question 4: can genomic and molecular information replace the mantle cell lymphoma international prognostic index for prognosis, and how can we incorporate this information into a precision approach to therapy?
Summary